| |
| |
|
| Insider
Information: |
Tepper Robert I |
| Relationship: |
10% Owner |
| City: |
Cambridge, |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
23 |
|
| Direct
Shares |
39,892,982 |
|
|
Indirect Shares
|
23,508,369 |
|
|
| Direct
Value |
$797,407,994 |
|
|
|
Indirect Value
|
$518,395,279 |
|
|
| Total
Shares |
63,401,351 |
|
|
| Total
Value |
$1,315,803,274 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
15
|
|
Stock
price went up :
|
0
|
7
|
| Stock
price went down : |
0
|
8
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 239.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Millennium Pharmaceuticals Inc |
MLNM |
President, R&D |
2007-02-12 |
105,137 |
2007-02-12 |
7,116 |
Premium* |
|
|
Bluebird Bio, Inc. |
BLUE |
Director, 10% Owner |
2015-02-03 |
89,017 |
2015-02-03 |
0 |
Premium* |
|
|
Carisma Therapeutics Inc |
CARM |
10% Owner |
|
0 |
2014-02-05 |
330,708 |
Premium* |
|
|
Dare Bioscience Inc |
DARE |
Director |
2014-04-10 |
18,954 |
|
0 |
Premium* |
|
|
Sage Therapeutics, Inc. |
SAGE |
10% Owner |
2016-08-19 |
3,170,750 |
2015-01-16 |
0 |
Premium* |
|
|
Larimar Therapeutics Inc |
LRMR |
10% Owner |
2015-07-23 |
0 |
2015-03-24 |
0 |
Premium* |
|
|
Foundation Medicine, Inc. |
FMI |
10% Owner |
2015-05-14 |
0 |
|
0 |
Premium* |
|
|
Blueprint Medicines Corp |
BPMC |
10% Owner |
2017-02-27 |
3,770,987 |
|
0 |
Premium* |
|
|
Global Blood Therapeutics, Inc. |
GBT |
10% Owner |
2017-04-06 |
229,773 |
2017-04-06 |
4,760,904 |
Premium* |
|
|
Cytomx Therapeutics, Inc. |
CTMX |
10% Owner |
2017-10-18 |
3,668,070 |
2017-10-04 |
4,320,348 |
Premium* |
|
|
Voyager Therapeutics, Inc. |
VYGR |
10% Owner |
2023-02-02 |
3,271,556 |
|
0 |
Premium* |
|
|
Editas Medicine, Inc. |
EDIT |
10% Owner |
2016-08-16 |
3,906,176 |
2016-02-08 |
0 |
Premium* |
|
|
Jounce Therapeutics Inc |
JNCE |
Director, 10% Owner |
2017-02-01 |
0 |
2017-02-01 |
3,048,780 |
Premium* |
|
|
Kala Pharmaceuticals, Inc. |
KALA |
Director |
2017-07-25 |
0 |
2017-07-25 |
1,621,092 |
Premium* |
|
|
Rhythm Pharmaceuticals, Inc. |
RYTM |
10% Owner |
2017-10-10 |
3,981,437 |
2017-10-10 |
0 |
Premium* |
|
|
Allena Pharmaceuticals, Inc. |
ALNA |
Director, 10% Owner |
2017-11-06 |
2,790,964 |
2017-11-06 |
0 |
Premium* |
|
|
Neon Therapeutics, Inc. |
NTGN |
Director, 10% Owner |
2018-06-29 |
0 |
2020-05-06 |
0 |
Premium* |
|
|
Constellation Pharmaceuticals Inc |
CNST |
Director, 10% Owner |
2018-07-23 |
0 |
2018-08-22 |
3,034,083 |
Premium* |
|
|
Fulcrum Therapeutics, Inc. |
FULC |
10% Owner |
2022-12-13 |
2,118,391 |
2022-12-13 |
2,343,154 |
Premium* |
|
|
Revolution Medicines, Inc. |
RVMD |
10% Owner |
2022-06-08 |
5,233,388 |
2020-09-09 |
1,909,317 |
Premium* |
|
|
Nurix Therapeutics, Inc. |
NRIX |
10% Owner |
2020-07-28 |
5,422,549 |
2020-07-28 |
0 |
Premium* |
|
|
Decibel Therapeutics, Inc. |
DBTX |
10% Owner |
2021-02-11 |
47,169 |
|
0 |
Premium* |
|
|
Pliant Therapeutics, Inc. |
PLRX |
10% Owner |
2022-11-29 |
2,068,664 |
2022-11-29 |
2,132,867 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
134 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 4 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| MLNM |
Millennium Pharmaceutical... |
President, R&D |
• – – |
2004-01-02 |
4 |
S |
$18.56 |
$371,200 |
D/D |
(20,000) |
18,999 |
|
- |
|
| MLNM |
Millennium Pharmaceutical... |
President, R&D |
• – – |
2004-01-02 |
4 |
OE |
$3.47 |
$95,373 |
D/D |
20,000 |
38,999 |
|
- |
|
| MLNM |
Millennium Pharmaceutical... |
President, R&D |
• – – |
2004-02-02 |
4 |
S |
$17.65 |
$353,000 |
D/D |
(20,000) |
18,999 |
|
- |
|
| MLNM |
Millennium Pharmaceutical... |
President, R&D |
• – – |
2004-02-02 |
4 |
OE |
$4.95 |
$99,066 |
D/D |
20,000 |
38,999 |
|
- |
|
| MLNM |
Millennium Pharmaceutical... |
President, R&D |
• – – |
2004-02-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,000 |
16,999 |
|
- |
|
| MLNM |
Millennium Pharmaceutical... |
President, R&D |
• – – |
2004-03-01 |
4 |
S |
$17.95 |
$359,000 |
D/D |
(20,000) |
16,999 |
|
- |
|
| MLNM |
Millennium Pharmaceutical... |
President, R&D |
• – – |
2004-03-01 |
4 |
OE |
$4.72 |
$94,376 |
D/D |
20,000 |
36,999 |
|
- |
|
| MLNM |
Millennium Pharmaceutical... |
President, R&D |
• – – |
2004-04-01 |
4 |
S |
$17.00 |
$340,000 |
D/D |
(20,000) |
16,999 |
|
- |
|
| MLNM |
Millennium Pharmaceutical... |
President, R&D |
• – – |
2004-04-01 |
4 |
OE |
$4.72 |
$96,718 |
D/D |
20,000 |
36,999 |
|
- |
|
| MLNM |
Millennium Pharmaceutical... |
President, R&D |
• – – |
2004-04-13 |
4 |
S |
$17.55 |
$95,104 |
I/I |
(5,416) |
0 |
|
- |
|
| MLNM |
Millennium Pharmaceutical... |
President, R&D |
• – – |
2004-08-30 |
4 |
GD |
$0.00 |
$0 |
D/D |
500 |
17,334 |
|
- |
|
| MLNM |
Millennium Pharmaceutical... |
President, R&D |
• – – |
2005-09-15 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
65,671 |
|
- |
|
| MLNM |
Millennium Pharmaceutical... |
President, R&D |
• – – |
2006-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
59,000 |
124,968 |
|
- |
|
| MLNM |
Millennium Pharmaceutical... |
President, R&D |
• – – |
2006-07-31 |
4 |
OE |
$3.94 |
$295,313 |
D/D |
75,000 |
202,375 |
|
- |
|
| MLNM |
Millennium Pharmaceutical... |
President, R&D |
• – – |
2006-08-09 |
4 |
S |
$9.87 |
$16,779 |
D/D |
(1,700) |
200,675 |
|
- |
|
| MLNM |
Millennium Pharmaceutical... |
President, R&D |
• – – |
2006-10-30 |
4 |
AS |
$11.84 |
$712,121 |
D/D |
(60,000) |
142,375 |
0 |
- |
|
| MLNM |
Millennium Pharmaceutical... |
President, R&D |
• – – |
2006-11-20 |
4 |
S |
$11.49 |
$172,432 |
D/D |
(15,000) |
127,375 |
0 |
- |
|
| MLNM |
Millennium Pharmaceutical... |
President, R&D |
• – – |
2007-02-12 |
4 |
AS |
$11.36 |
$255,600 |
D/D |
(22,500) |
105,137 |
0 |
- |
|
| NRIX |
Nurix Therapeutics, Inc. |
10% Owner |
– – • |
2020-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
5,422,549 |
5,422,549 |
0 |
- |
|
| NTGN |
Neon Therapeutics, Inc. |
Director |
– • • |
2018-06-29 |
4 |
A |
$0.00 |
$0 |
I/I |
0 |
0 |
0 |
- |
|
| NTGN |
Neon Therapeutics, Inc. |
Director |
– • • |
2020-05-06 |
4 |
D |
$0.00 |
$0 |
I/I |
(9,741,636) |
0 |
0 |
- |
|
| PLRX |
Pliant Therapeutics, Inc. |
10% Owner |
– – • |
2022-09-20 |
4 |
AS |
$0.00 |
$0 |
D/D |
(2,000,000) |
3,839,160 |
0 |
- |
|
| PLRX |
Pliant Therapeutics, Inc. |
10% Owner |
– – • |
2022-11-29 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,000,000) |
1,839,160 |
0 |
- |
|
| RVMD |
Revolution Medicines, Inc... |
10% Owner |
– – • |
2020-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
10,522,342 |
1,909,317 |
0 |
- |
|
| RVMD |
Revolution Medicines, Inc... |
10% Owner |
– – • |
2020-09-09 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,000,000) |
8,024,031 |
0 |
- |
|
134 Records found
|
|
Page 4 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
